Simeone, Ester
Scognamiglio, Giosuè
Capone, Mariaelena
Giannarelli, Diana
Grimaldi, Antonio M.
Mallardo, Domenico
Madonna, Gabriele
Curvietto, Marcello
Esposito, Assunta
Sandomenico, Fabio
Sabbatino, Francesco
Bayless, Nicholas L.
Warren, Sarah
Ong, SuFey
Botti, Gerardo
Flaherty, Keith T.
Ferrone, Soldano
Ascierto, Paolo A.
Clinical trials referenced in this document:
Documents that mention this clinical trial
A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation
https://doi.org/10.1186/s12967-020-02680-7
Funding for this research was provided by:
Roche Italia
NanoString Technologies
Ricerca Corrente
Article History
Received: 13 October 2020
Accepted: 14 December 2020
First Online: 6 January 2021
Ethics approval and consent to participate
: The study gained full approval from the Ethical Committee of the Istituto Nazionale Tumori IRCCS–Fondazione “G Pascale” on 15 January 2014. All patients have provided written informed consent to participate in the study prior to being screened.
: Not applicable.
: E. Simeone received honoraria from Bristol Myers Squibb, Novartis and Merck Sharp & Dohme. The other authors declare no potential competing interests. A.M.Grimaldi has/had an advisory and consultant role Bristol Myers Squibb, Merck Sharp & Dohme and Novartis. He received travel support from Bristol Myers Squibb, Merck Serono, Pierre Fabre, Roche-Genentech and Novartis. S Warren and S. Ong are/were employees and stockholders in NanoString Technologies. K.T. Flaherty served(s) on the Board of Directors of Clovis Oncology, Strata Oncology, Vivid Biosciences, Checkmate Pharmaceuticals, and Loxo Oncology; Corporate Advisory Board of X4 Pharmaceuticals; Scientific Advisory Boards of PIC Therapeutics, Sanofi, Amgen, Asana, Adaptimmune, Fount, Aeglea, Shattuck Labs, Tolero, Apricity, Oncoceutics, Fog Pharma, Neon, Tvardi, xCures, Monopteros, Vibliome, and consultant to Lilly, Novartis, Genentech, BMS, Merck, Takeda, Verastem, Boston Biomedical, Pierre Fabre, and Debiopharm; as well as research funding from Novartis and Sanofi. P.A. Ascierto has/had a consultant/advisory role for Bristol Myer Squibb, Roche-Genentech, Merck Sharp & Dohme, Array, Novartis, Merck Serono, Pierre Fabre, Incyte, NewLink Genetics, Genmab, Medimmune, AstraZeneca, Syndax, SunPharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Boehringer-Ingelheim. He also received research funds from Bristol Myers-Squibb, Roche-Genentech, Array, and travel support from MSD.